Is Globus Medical (GMED) Cheap Following Its Pullback And Integration Driven Valuation Case?
Globus Medical (GMED) has come into focus after its recent share performance and valuation metrics attracted fresh attention from investors. The stock last closed at $80.48, with recent returns showing a mixed short term picture.
Over the past year, Globus Medical has seen short term share price pressure, with the 7 day share price return down 2.99% and the year to date share price return down 7.81%. However, the 1 year total shareholder return of 34.36% and 3 year total shareholder return of 52.11% point to longer term momentum that has so far rewarded patient holders.
Compare the recent performance of Globus Medical with a hand picked 50 high quality undervalued stocks that also pair grounded fundamentals with potential for stronger long term compounding.
Globus Medical now trades well below both analyst targets and one estimate of intrinsic value, creating a wide valuation gap. After the recent share pullback, where does fair value realistically line up for this stock?
Most Popular Narrative: 22% Undervalued
Globus Medical's most followed valuation narrative points to a fair value of $103.23 versus the last close at $80.48, which signals a sizeable gap that analysts link directly to earnings power and margin assumptions.
Successful integration and synergy capture from the NuVasive and Nevro acquisitions are providing opportunities for increased cross-selling, cost efficiencies, and realization of deferred tax assets, which are expected to drive margin expansion, boost earnings, and enhance recurring cash flows in upcoming years.
Want to see what sits behind that confidence in Globus Medical? The narrative leans heavily on rising profitability, steady revenue expansion and a future earnings multiple that needs firm execution to hold. Curious which specific margin path and growth curve are baked into that fair value? The full narrative lays those assumptions out in detail.
Result: Fair Value of $103.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Globus Medical narrative still depends on smooth NuVasive and Nevro integration and steadier international growth, and setbacks on either front could quickly challenge those fair value assumptions.
Find out about the key risks to this Globus Medical narrative.
Next Steps
The sentiment around Globus Medical is clearly optimistic, so now is the time to look at the numbers yourself and decide if they stack up for you. To see why some investors are focusing on the potential upside, review the 5 key rewards
Looking for more investment ideas beyond Globus Medical?
If Globus Medical interests you, do not stop here. Broaden your watchlist with other focused ideas that match your style and keep your capital working thoughtfully.
- Target potential mispricing by reviewing a curated 50 high quality undervalued stocks that combine grounded fundamentals with room for further upside.
- Strengthen capital preservation by scanning a 74 resilient stocks with low risk scores chosen for resilient balance sheets and steadier risk profiles.
- Hunt for future leaders early by checking a 19 high quality undiscovered gems that pair solid financials with lower market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com